Rocket Pharmaceuticals, Inc.
Rocket Pharmaceuticals, Inc. (RCKT) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
rckt · stock forecast · 19 analysts (3M) · FMP · updated Jun 8, 2026
Analyst Rating & Consensus
Based on 19 Wall Street analysts in the past 3 months
Buy
19 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$5.00
Consensus
$5.00
+85.2% upside
Low
$5.00
Median: $5 · Last Close: $2.70
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Short-Term Price Prediction
Low ActivityAlgorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-09 | $2.57 | ↓ 4.71% |
1-day model range: $2.53–$2.61. Peak: $2.61 (-4.71%).
Long-Term Stock Price Prediction
Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031
| Year | Avg Price | Change |
|---|---|---|
| 2027 | — | -35.3% |
| 2028 | — | -46.8% |
| 2029 | — | -51.5% |
| 2030 | — | -53.6% |
| 2031 | — | -54.6% |
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Insufficient Trading Activity — Sentiment Signals Disabled
This stock has very low trading volume (ZOMBIE condition). Sentiment analysis requires sufficient price action. RSI and MACD values below are still shown for reference.
Moving Averages · RCKT · Jun 8, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2026-05-11 | Chardan Capital | Maintains | Buy→Buy |
| 2026-03-30 | B of A Securities | Maintains | Buy→Buy |
| 2026-03-27 | Chardan Capital | Maintains | Buy→Buy |
| 2026-03-02 | Goldman Sachs | Maintains | Sell→Sell |
| 2026-02-27 | Cantor Fitzgerald | Maintains | Overweight→Overweight |
| 2025-11-18 | B of A Securities | Maintains | Buy→Buy |
| 2025-11-18 | JP Morgan | Downgrade ↓ | Overweight→Underweight |
| 2025-10-14 | Chardan Capital | Maintains | Buy→Buy |
| 2025-10-03 | Leerink Partners | Maintains | Market Perform→Market Perform |
| 2025-08-20 | B of A Securities | Upgrade ↑ | Neutral→Buy |
Wall Street analysts have recently issued updated ratings on Rocket Pharmaceuticals, Inc. (RCKT) stock. Of the recent 104 rating actions, 1 were upgrades and 7 were downgrades. 19 analysts currently cover RCKT.
Analyst Recommendation Trends
RCKT analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 4 to 1 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$2M
↓ 96.5% YoY
Revenue Next Year
$20M
↑ 765.4% YoY
EPS This Year
$-0.28
EPS Next Year
$-1.27
↑ 362.4% YoY
EPS ForecastReported vs Estimated
Analysts forecast RCKT EPS of $-0.28 for the current fiscal year, based on estimates from 9 analysts. The RCKT revenue forecast is $2M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The RCKT stock forecast is supported by two independent data sources: analyst consensus ratings from 19 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus RCKT price target is $5.00 (+85.2% upside), with an analyst consensus of Buy.
The RCKT short-term stock prediction for tomorrow is $2.57 (-4.71%). The RCKT stock prediction for 2030 projects a range of $1–$1.
Rocket Pharmaceuticals, Inc. trades on NASDAQ under the ticker RCKT. The RCKT stock outlook for 2027 is broadly positive, supported by a Buy consensus among 68% of covering analysts.
Frequently asked questions
RCKT forecast · 8 questionsAccording to 19 Wall Street analysts, the average 12-month RCKT price target is $5.00, with a high forecast of $5.00 and a low of $5.00. The median price target is shown in the chart above when available. This implies +85.2% potential upside from the current price of $2.70.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.